[Federal Register Volume 83, Number 87 (Friday, May 4, 2018)]
[Notices]
[Page 19787]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09533]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-1534]
Sun Pharmaceutical Industries, Ltd.; Withdrawal of Approval of
Three Abbreviated New Drug Applications
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is
withdrawing approval of three abbreviated new drug applications (ANDAs)
held by Sun Pharmaceutical Industries, Ltd., c/o Sun Pharmaceutical
Industries, Inc. (Sun Pharmaceutical). These drug products are no
longer marketed, and Sun Pharmaceutical has requested that the approval
of the applications be withdrawn.
DATES: Approval is withdrawn as of June 4, 2018.
FOR FURTHER INFORMATION CONTACT: Trang Tran, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945,
[email protected].
SUPPLEMENTARY INFORMATION: Sun Pharmaceutical has informed FDA that
these drug products are no longer marketed and requested that FDA
withdraw approval of the applications. Sun Pharmaceutical has also
waived its opportunity for a hearing and requested withdrawal of
approval under a Consent Decree of Permanent Injunction (Decree)
entered in United States v. Ranbaxy Laboratories, Ltd. et al., JFM 12-
250 (D. Md.) on January 26, 2012. The Decree specifies that Sun
Pharmaceutical must never submit another application to FDA for these
withdrawn drugs and must never transfer these ANDAs to a third party.
------------------------------------------------------------------------
Application No. Drug Applicant
------------------------------------------------------------------------
ANDA 065174..................... Clarithromycin Sun Pharmaceutical
Tablets USP, 250 Industries, Ltd.,
milligrams (mg) c/o Sun
and 500 mg. Pharmaceutical
Industries, Inc.,
2 Independence
Way, Princeton,
NJ 08540.
ANDA 065382..................... Clarithromycin for Do.
Oral Suspension
USP, 125 mg/5
milliliters (mL)
and 250 mg/5 mL.
ANDA 075747..................... Ciprofloxacin Do.
Tablets USP,
Equivalent to
(EQ) 250 mg base,
EQ 500 mg base,
and EQ 750 mg
base.
------------------------------------------------------------------------
Therefore, approval of the applications listed in the above table,
and all amendments and supplements thereto, is hereby withdrawn as of
June 4, 2018. Introduction or delivery for introduction into interstate
commerce of products without approved new drug applications violates
section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 331(a) and (d)).
Dated: May 1, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-09533 Filed 5-3-18; 8:45 am]
BILLING CODE 4164-01-P